Adnkronos Rome, October 13 (Adnkronos Salute) – FedEmo, the Federation of Hemophilia Associations, together with the Association of Patients with Dysimmune Neuropathies (CIDP Aps) and the Association of Primary Immunodeficiencies (AIP Aps), is calling for increased efficiency and the achievement of national self-sufficiency in blood and plasma-derived products for the proper treatment of patients receiving these products. The appeal, the Federation clarifies in a statement, concerns both planning, with timely approval of the self-sufficiency plan within the timeframe necessary for its implementation, and encouraging and adjusting the achievement of the minimum collection target, increasing it from the current 70% to 90% of the requirement.
According to FedEmo, the current collection targets "are clearly not sufficient" and it hopes that "they can be raised and achieved to overcome the critical issues, or potential ones, highlighted by the Critical Medicine Act and the Union List of Critical Medicines regarding plasma-derived drugs – human immunoglobulins and albumin in particular – in terms of their supply and availability."
The Federation, the statement emphasizes, recognizes the vital importance of plasma derivatives and, with gratitude, "the historical and ongoing value of the generosity of Italian donors and the professionalism of healthcare professionals in the transfusion field: a value," it emphasizes, "determined by the will and skills acquired, which must absolutely be supported and encouraged at the national and regional levels, with far-sighted, system-wide policies, to protect the health and dignity of patients, on the one hand, by fully implementing what is already established by law and, on the other, it concludes, by adequately addressing fiscal policies and international duties that could compromise the provision of vital therapies."